Maryam B. Lustberg
Ohio State University
272 Papers
452 Citations
Maryam B. Lustberg is an academic researcher from Ohio State University. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 31, co-authored 190 publications. Previous affiliations of Maryam B. Lustberg include James Cancer Hospital & University of Maryland Marlene and Stewart Greenebaum Cancer Center.
Chat about Author
Papers
Patterns of Neuropathy in ALL Patients Treated with Vincristine Based Regimens with and without Tyrosine Kinase Inhibitors
Audrey M. Sigmund,Michelle A. Fullmer,Rina Li,Tracelyn Freeman,Bryant Clemons,Stefanie Quimjian,Heather Niccum Haag,Ai Ni,Shuiying Hu,Alice S. Mims,Gretchen A. McNally,Maryam B. Lustberg,Bhavana Bhatnagar +12 more
TL;DR: The most common treatment regimen was hyper-CVAD (50.5%), followed by the CALGB 10403 (Stock Blood 2019) regimen (29.5%) as mentioned in this paper .
The mutational profile of ER-, PR+, HER2- metastatic breast cancer.
Neal A. Fischbach,Richard Huang,Maryam B. Lustberg,Maureen Pelletier,Lajos Pusztai,Smruthy Sivakumar,Ethan Sokol,Jeffrey S. Ross,Mia A. Levy +8 more
TL;DR: The mutational profile for ER-PR+Her2- metastatic breast cancer more closely resembles TNBC than ER+ breast cancer, and molecular profiling may be a useful adjunct to optimize treatment strategies for this rare subset of cancers.
Abstract P6-09-05: Using Mixed Methods to Examine Clinician and Patient Use of Terminology to Describe Trastuzumab Biosimilars
Elizabeth Lerner Papautsky,Devika Salunke,Hannah Montague,Martha Carlson,S. Johnson,Deanna J. Attai,Maryam B. Lustberg +6 more
TL;DR: Papautsky et al. as mentioned in this paper analyzed open-ended questions from surveys (n = 143 breast cancer patients, n = 33 medical oncologists) and interviews and found that terminology used to refer to trastuzumab biosimilars is variable across patients and some is not representative of the formal definition.
Quantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients
Jennifer M. Kwan,Amit Arbune,Mariana L. Henry,Rose Hu,Wei Wei,Seohyuk Lee,Juan Lopez-Mattei,Avirup Guha,Steffen Huber,Anna S. Bader,Judith L. Meadows,Albert J. Sinusas,Hamid Mojibian,Dana Peters,Maryam B. Lustberg,Sarah C. Hull,Lauren A. Baldassarre +16 more
TL;DR: In this paper , the authors evaluated the associations of circumferential and global longitudinal strain (GLS) correlations with cardiovascular outcomes including myocardial infarction, systolic dysfunction, diastolic dysfunction and arrhythmias.
Abstract P2-02-05: Patterns of adjuvant bone modifying agent use in patients with early-stage breast cancer in the United States
TL;DR: Grossberg et al. as mentioned in this paper evaluated the use of adjuvant bisphosphonates in the United States before and after publication of the 2017 ASCO/CCO guidelines (ACGD).